Nat. Med. 10, 145–147 (2004).
The complete trial schema was omitted from the article. The protocol is outlined below.Table 1
Additional information
The online version of the original article can be found at 10.1038/nm988
Rights and permissions
About this article
Cite this article
Willett, C., Boucher, Y., di Tomaso, E. et al. Correction: Corrigendum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 649 (2004). https://doi.org/10.1038/nm0604-649c
Issue Date:
DOI: https://doi.org/10.1038/nm0604-649c
This article is cited by
-
Evaluation of cytotoxic T lymphocyte-mediated anticancer response against tumor interstitium-simulating physical barriers
Scientific Reports (2020)
-
The Polyclonal Antibodies Induced by VBP3 Complex Peptide Targeting Angiogenesis and Tumor Suppression
International Journal of Peptide Research and Therapeutics (2017)
-
Non-Uniform Plasma Leakage Affects Local Hematocrit and Blood Flow: Implications for Inflammation and Tumor Perfusion
Annals of Biomedical Engineering (2007)
-
Reply to “PET concerns in bevacizumab treatment”
Nature Medicine (2004)
